Exponent, Inc. — Form 10-Q Summary
Reporting period: The supplied filing is for the quarter ended July 3, 2015, with six-month results through that date. This does not match the request metadata of 2014 Q2.
Business context and financial performance
Exponent provides engineering and scientific consulting services. All dollar amounts below are in millions unless noted; quarterly and six-month comparisons are against the corresponding 2014 periods.
| Metric | Q2 2015 | Q2 2014 | First six months 2015 | First six months 2014 |
|---|---|---|---|---|
| Revenue | $79.9 (+4.3%) | $76.6 | $160.2 (+5.0%) | $152.5 |
| Revenue before reimbursements | $75.3 (+4.1%) | $72.3 | $151.4 (+4.2%) | $145.3 |
| Operating income | $18.7 (+16.3%); 23.4% margin | $16.1; 21.0% margin | $33.7 (+11.8%) | $30.2 |
| Net income | $11.7 (+3.8%) | $11.3 | $22.0 (+7.9%) | $20.4 |
| Diluted EPS | $0.43 | $0.41 | $0.80 | $0.73 |
| Operating cash flow | Not provided for the quarter alone | $14.8 | $10.7 |
Engineering and Other Scientific revenue rose 7.4% in Q2 and 7.2% for the half, led by higher billable hours and demand across several engineering practices. Environmental and Health revenue declined 3.6% in Q2 and 1.0% for the half, reflecting weaker health-center demand and unfavorable currency translation.
Liquidity, capital allocation, and balance sheet
- At July 3, 2015, cash and cash equivalents were $131.9 million and short-term investments were $17.9 million, totaling $149.9 million, versus $154.4 million at January 2, 2015. Management said available resources should cover working capital, capital spending, commitments, repurchases, dividends, and other needs for at least 12 months.
- Six-month investing cash flow was a $4.8 million source, mainly reflecting investment maturities; financing cash flow was a $17.2 million use, including $8.0 million of dividends, $7.0 million of repurchases, and payroll taxes on restricted stock units. Cash increased $2.4 million during the period.
- Total liabilities were $108.5 million and stockholders’ equity was $259.6 million. The balance sheet reports no borrowings or other debt.
- The company declared dividends of $0.15 per share in each of the first two 2015 quarters, up from $0.125 per share in 2014. A further $0.15 dividend was declared for payment in September 2015, subject to the board’s declaration. Remaining repurchase authorization was $28.1 million at July 3.
Changes, outlook, and risks
- Q2 billable hours increased 4% to 287,000 and utilization improved to 74% from 72%; technical full-time equivalent employees increased 2% to 750. Management cited strong, diverse demand for reactive and proactive work.
- Management said one major investigation ended in July 2015, with future work on it expected to be minimal. It also expected a year-over-year decline in technology-development activity, citing defense-spending constraints and the withdrawal of U.S. and U.K. combat troops from Afghanistan.
- Management expects compensation costs, other operating expenses, and general and administrative expenses to rise as it adds talent and invests in infrastructure and business development. Reimbursable expenses can vary with project mix.
- Q2 net income benefited from operating-income growth, while other income fell to $0.6 million from $2.3 million, largely because deferred-compensation plan asset changes were less favorable year over year. Six-month EBITDA as a percentage of revenue before reimbursements was 25.8%, versus 25.0%; EBITDA and EBITDAS are non-GAAP measures.
- Key risks identified include changes in demand and economic conditions, engagement timing, competition and pricing, lack of backlog, attracting and retaining employees, regulation and tort reform, claims, and foreign exchange. The company does not hedge foreign currency exposure. Management reported no material change to previously disclosed risk factors and no material legal proceedings; ordinary-course claims remain possible.
- The May 2015 two-for-one stock split is reflected retroactively in share and per-share data. Management was evaluating the new revenue-recognition standard, effective for the company in fiscal 2018, and had not selected a transition method.
Important facts for investors to verify
- Confirm the intended filing period: this document covers Q2 2015, not Q2 2014.
- Track whether growth in Engineering and Other Scientific offsets continued weakness in Environmental and Health, including currency effects.
- Assess whether utilization, billable hours, and hiring support revenue growth while compensation and infrastructure costs increase.
- Review the cash-flow impact of dividends and repurchases, and whether capital returns remain consistent with operating cash generation.
- Monitor the anticipated technology-development slowdown, foreign-exchange exposure, and any developments in legal or contractual contingencies.